The four viruses that pose the biggest threat of a new pandemic in the UK
Health officials in Britain have published a first-of-its-kind list of the disease-causing viruses they believe pose the greatest risk to humans - including four viruses highlighted as pandemic risks.
The UK Health Security Agency (UKHSA) released a 'priority pathogen list' including deadly organisms such as monkeypox, ebola and norovirus.
Scientists analysed the potential of the organisms to cause an epidemic (a regional outbreak) or a pandemic (a global outbreak).
The idea of the new tool is to encourage scientific research and speed up vaccine development, with climate change creating new disease risks, alongside resistance to antibiotics.
The UKHSA hopes to see scientific strides made on pathogen families including the coronavirus family, the norovirus family and the family of viruses which includes avian flu, alongside a virus family which includes Nipah virus.
'We live at the time of increasing challenges and increasing risks from infectious diseases," Dr Isabel Oliver, chief scientific officer for UKHSA, said. "But at the same time we have got, thanks to scientific advancement, better tools than we've ever had to protect health against these threats.
'Having said that there are areas where we still need more or better diagnostics, vaccines and medicines and therapeutics, and this tool has been designed to help inform the work of government research funders, but also our partners in industry and academia who are critical to the development of these tools that we so desperately need.'The 'Coronaviridae' family, which includes the virus that sparked the COVID-19 pandemic, still holds 'high' pandemic potential, researchers warn.
The report warns of the risk of animal-to-human transmission, with a particular focus on the Middle East.
'Of the highest priority pathogens identified by the UKHSA, no one could argue with the inclusion of coronaviruses," Prof Mark Woolhouse, Professor of Infectious Disease Epidemiology, and Director of the Tackling Infections to Benefit Africa, University of Edinburgh, said. 'A key recommendation of the UK COVID Inquiry's Interim Report for Module 1 (Preparedness) was that prior to 2020 the UK was overly focussed on the risk of an influenza pandemic. When COVID arrived, it took too long to adjust our response to a different threat, which was part of the reason we ended up in lockdown.
'Since the pandemic, there have been many initiatives to better understand the diversity of pandemic threats that the UK and the world may face in the coming years. The UKHSA's pathogen prioritization exercise is a welcome contribution to this global effort.'
The flu family (or 'Orthomyxoviridae') includes influenza viruses, as well as viruses that primarily infect birds, pigs and cattle.
The flu family is described as high risk for both pandemics and epidemics.
The report warns that the risk from the viruses is likely to increase due to climate change, and that Asia poses a particular risk in geographical spread.
Prof Emma Thomson, Director of the MRC-University of Glasgow Centre for Virus Research, said: "From a scientific perspective, the list is particularly helpful in identifying gaps in our current understanding of high-risk pathogen families and the areas where new research and countermeasure development are most urgently needed.
"Many of the listed families—such as orthomixidae — are already recognised as significant threats, but the tool also highlights less well-characterised families where pandemic or epidemic potential remains underexplored."
The Paramyxoviridae family of viruses includes diseases such as measles as well as Nipah virus.
The UKHSA warns that the risk of such viruses is likely to grow in our warning climate, highlighting Asia as a particular risk.
Nipah virus was highlighted among these viruses: the virus spreads among bats, and kills up to 75% of infected humans.
While there is an effective virus against measles, immunisation rates need to be at 95% for it to work, which has seen outbreaks in areas in the U.S. high in anti-vaccine sentiment.
The risks of such viruses are increasing as humans live in proximity to animals.
The Picornaviridae includes virsues including the rhinovirus which is the main cause of the common cold, and enterovirus which causes polio, as well as the virus behind hepatitis A.
The UKHSA report highlights that such viruses can spread through food and water as well as through breath.
Picornaviridae are spread worldwide.
Of particular concern is that there are few vaccines or therapeutic treatments for the viruses, with just one candidate vaccine in trial at present.
The new UKHSA tool will be updated annually, but government scientists warn it represents a 'snapshot in time' and must be used alongside other information sources.
But other experts have warned that focusing on 'known' threats may pose its own problems.
Prof Jose Vazquez-Boland, Chair of Infectious Diseases, University of Edinburgh described prioritising well-known diseases as a "double-edged sword".
Other experts suggested that there needs to be more focus on emerging threats - including 'Disease X', a new virus that may emerge from wildlife.
Prof Emma Thomson, Director of the MRC-University of Glasgow Centre for Virus Research, said: 'It is essential that this list remains dynamic and responsive to emerging threats. History has shown that pandemic risks can arise from unexpected sources. For example, coronaviruses and retroviruses were not widely regarded as major threats before SARS-CoV-1 and HIV-1 emerged, respectively.
"The concept of Disease X also remains critical in this context. There are an estimated 320,000 undiscovered viruses in wildlife that could have spillover potential. Enhanced technologies for virus discovery and characterisation—such as unbiased metagenomic sequencing and improved surveillance—will be essential to ensure that novel pathogens are rapidly identified and assessed for pandemic potential."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil
Next-generation technologies will help increase the agility and efficiency of genetic sequencing to tackle several diseases SAO PAULO, June 5, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, has just expanded its partnership with the Diagnostic Support Unit (UNADIG), a non-profit laboratory of the Oswaldo Cruz Foundation (FIOCRUZ), one of Brazil's leading scientific institutions, to support public health in the country. MGI's first scientific collaboration with UNADIG was established during the COVID-19 pandemic. With the MGISP-960 extractor equipment from MGI, UNADIG was able to process more than 3 million samples from across the country during this period. With the end of the pandemic, UNADIG expanded its portfolio and included different methodological platforms in its laboratory facilities (chemiluminescence, Elisa, photometry, immunoturbidimetry, and indirect potentiometry), as well as genetic sequencing. The new agreement between UNADIG and MGI will enable maintain the molecular tests (RT-PCR) but advances in DNA-based testing. UNADIG has two large high-processing laboratories. The the Clinical Diagnostic Laboratory (DCLIN) has a daily processing capacity of around 29,000 samples, and the Molecular Diagnostic Laboratory (DIMOL) can process between 9,000 and 15,000 RT-PCR samples. In 2025, with the sequencing support of MGI, a process in molecular genetics will begin with the capacity to process over 2,000 samples weekly for the diagnosis of infectious, genetic, and main types of cancer (breast, ovarian, colorectal and prostate), in addition of individual gene sequencing for sporadic or hereditary cancers. "The goal of this collaboration is to help transform healthcare delivery, with a focus on efficiency and accessibility, as it will contribute to expanding access for the Brazilian population to high-complexity laboratory tests with greater speed and reduced costs. This will accelerate the diagnosis and treatment of oncological and epidemiological diseases, strengthening the country's response to outbreaks and epidemics", Carlos Carpio, Senior Commercial Director of MGI Latin America and General Manager for Brazil, explains. To expand its operational and analytical capacity for sample and test processing, UNADIG has acquired state-of-the-art equipment from MGI, including 14 units MGISP-960 nucleic acid extractor; 1 unit MGISP-100 automated genomic library preparation system; 2 units DNBSEQ-G400 and 1 unit DNBSEQ-T7 sequencers; and 1 unit ZTRON platform for genomic data storage and analysis. These technologies also ensure greater speed and accuracy in processing, while enhancing sample handling safety and reducing the risk of contamination. "Precision medicine brings significant benefits to patients and to the public health system, enabling early diagnoses, more effective treatments and the optimization of clinical protocols. This results in cost savings, waste reduction and greater effectiveness of tests and therapies. MGI's equipment, which allows automated processes, helps us achieve these goals", Erika Martins de Carvalho, General Coordinator of UNADIG-RJ of the Vice Presidency of Health Production and Innovation at Fiocruz, says. Increasing the presence in Brazil With the goal of making genetic sequencing more accessible, efficient and scalable through comprehensive solutions, MGI has been expanding its operations in Brazil. In 2024, the company inaugurated a Customer Experience Center in São Paulo, created to offer clinical laboratories and healthcare institutions a dedicated space for hands-on demonstrations. The center aims to enhance technical training and familiarity with MGI's technologies. Highly qualified professionals lead certified training sessions, presentations, evaluations and provide local support for new applications. Also in 2024, MGI established partnerships with Dasa, Grupo Sabin and Oncoclínicas&Co to expand the use of genetic sequencing in Brazil through the adoption of advanced technologies for genetic testing aimed at diagnosing cancers, rare diseases and other conditions, strengthening personalized medicine in the country. About MGI MGI Tech Co., Ltd. (or its subsidiaries, together referred to MGI), is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare and various other industries. Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and have established research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future. To learn more, please visit , Linkedin, X, and Youtube. View original content to download multimedia: SOURCE MGI TECH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Are you among adults who don't know you have diabetes, hypertension?
A significant number of adults in the U.S. don't know that they have high blood pressure, diabetes or bad total cholesterol numbers, which all contribute to the risk of death from cardiovascular disease. And awareness may be even worse now because COVID-19 disrupted preventive screenings. That's according to a new study in the journal JAMA Cardiology from researchers at Beth Israel Deaconess Medical Center, the Pritzker School of Medicine at the University of Chicago and the Harvard T.H. Chan School of Public Health. The research involved 15,269 nonpregnant adults 20 or older (average age 56.8 years) who had cardiovascular risk factors between 2013 and 2023, using the National Health and Nutrition Examination Survey. The researchers looked specifically at how many didn't know their own health status for those conditions, which was learned through a household interview and then a medical examination. 'The proportion of U.S. adults who were unaware of having hypertension increased significantly over the study period, particularly in young adults and women, while diabetes and high cholesterol level unawareness remained stable. By the 2021 to 2023 cycle, approximately 1 in 6 adults with hypertension and 3 in 10 with diabetes were unaware of their condition,' per the study. The adults who had been identified as having a cardiovascular risk factor but who reported not being told by a health professional that they had the factor were classified as unaware. 'Given declining cardiometabolic health in young adults,' the authors expressed concern that about one-third of those with hypertension, 2 in 5 with diabetes and 1 in 4 with high cholesterol are not aware of their own situation. They added that 'policy efforts to address these gaps in awareness are needed to prevent future cardiovascular events.' The researchers found that across the entire age range studied, 17.8% who had hypertension didn't know it in 2021-2023, compared to 14.6% in 2013-2014. The proportion of adults who didn't know they had diabetes did not change significantly, going from 27.5% to 28.9%. The share with high cholesterol who didn't know was also stable, at 11.5% and 11.9% respectively. But age made a difference. The proportion of young adults ages 20-44 who didn't know they had hypertension rose from 21.9% to 37.1%. Awareness of that didn't change for those 45 and older, or among different age groups who had undiagnosed diabetes or high cholesterol. Lack of awareness of having high blood pressure rose significantly over the study period in women, to 16.5%. All three of those conditions are treatable. Left untreated, however, they can cause severe problems or kill. They are considered 'modifiable risk factors' for cardiovascular disease. The Centers for Disease Control and Prevention reports that heart disease is the leading cause of death in the United States. It includes stroke, heart failure and atrial fibrillation. High cholesterol can lead to a buildup of plaque on artery walls, narrowing those blood vessels and limiting or blocking blood flow to and from the heart and other organs, per CDC. That can cause chest pain or a heart attack. It also raises the risk for heart disease and stroke, which are leading causes of death. High blood pressure or hypertension doesn't usually have symptoms, but can damage the heart, brain, kidneys and eyes. Making lifestyle changes or taking blood pressure medicines can reduce the risk, per CDC. People who have diabetes have twice the risk of heart disease and the risk climbs over time. High blood sugar damages blood vessels and the nerves that control the heart, per CDC. But medication and lifestyle changes can help there, too. Those with diabetes are also more apt to have high blood pressure and so-called 'bad' cholesterol — along with the increased risk those conditions bring. They are also more likely to experience heart failure, where the heart pumps less efficiently, which can also lead to a buildup of fluid in the lungs, making breathing both miserable and difficult. Cleveland Clinic reports that about half of U.S. adults have some form of cardiovascular disease and that 1 in 3 women die from it. Among the risk factors — besides hypertension, high cholesterol and type 2 diabetes — are tobacco use including vaping, genetics, lack of exercise, an unhealthy diet, overuse of alcohol, misuse of prescription and recreational drugs, some chronic autoimmune or inflammatory conditions, chronic kidney disease, and certain pregnancy-related complications. As reported by Medical News Today, researchers at the University of Copenhagen in Denmark found that those who don't know they have forms of heart disease and who have undetected obstructive coronary atherosclerosis have an eight-fold risk of heart attack. That same study suggested that nearly half of adults over 40 'may have such 'hidden' heart conditions.' The American Heart Association noted that there are other conditions that often go undiagnosed, including a 'potentially fatal buildup of abnormal proteins in the heart and other organs.' That condition, called transthyretin amyloidosis, is considered rare, but studies now suggest that it's a fairly common cause of heart failure in older adults, with the proteins found in the hearts of one-fourth of older adults at autopsy. That condition, like hypertension, diabetes and high cholesterol, is also treatable. But it has to be diagnosed and addressed. Undiagnosed heart disease is also responsible for a very large share of heart attacks that aren't caused directly by a blood clot, the association separately reported.

2 hours ago
CDC official who oversaw COVID vaccine recommendations resigns
An official at the Centers for Disease Control and Prevention who oversaw the agency's recommendations for COVID-19 vaccines has resigned, following a week of mixed messaging from federal health officials over who would be eligible for the shots. "My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role," Dr. Lakshmi Panagiotakopoulos wrote in her resignation letter obtained by ABC News. In her letter, Panagiotakopoulos said she resigned last Friday. Reuters first reported her resignation. Panagiotakopoulos co-led a part of the CDC's independent panel of vaccine advisers to review evidence for recommendations on COVID vaccines. In mid-April, the advisers had discussed the possibility of narrowing the recommendations for who should receive an annual COVID vaccine -- prioritizing those at higher risk such as adults over 65 or those with an underlying condition. Last week, Health and Human Services Secretary Robert F. Kennedy Jr. announced the removal of COVID vaccines from the immunization schedule for healthy children and healthy pregnant women. Later on Friday, the CDC updated the immunization schedule allowing all children to be eligible to receive COVID vaccines, now under a shared clinical decision-making model, which means parents can choose to get their children vaccinated with the advice of a doctor. The mixed messages prompted concern from some medical organizations. "American families deserve better," the American Academy of Pediatrics (AAP) said, in part, in a statement. "They deserve clear messages from all involved in their health, that are based on facts so they can continue to benefit from the success story of vaccines." The statement went on to say: "While the shared clinical decision-making model in the updated immunization schedule preserves families' choice, this model has consistently proven challenging to implement because it lacks clear guidance for the conversations between a doctor and a family. Doctors and families need straightforward, evidence-based guidance, not vague, impractical frameworks," the AAP statement added. Pregnant women were left without a recommendation on the CDC's immunization schedule as to whether or not to receive the COVID vaccine. Despite the change in recommendations from HHS, "the science has not changed," the American College of Obstetricians and Gynecologists (ACOG) said in part of a statement. "It is very clear that COVID-19 infection during pregnancy can be catastrophic and lead to major disability, and it can cause devastating consequences for families. The COVID-19 vaccine is safe during pregnancy, and vaccination can protect our patients and their infants after birth," the ACOG statement added. Federal officials had made the changes to the vaccine recommendations without the input of the CDC's independent panel of vaccine advisers and before their meeting set for late June, according to the public calendar. In the meeting, advisers were set to discuss their recommendation for who should be eligible for COVID vaccines including a vote on whether to narrow the recommendations. "Governmental guidance about vaccines is an important foundation that enables insurance coverage of—and therefore access to—vaccines, so changing government recommendations about which specific and limited populations should receive COVID-19 vaccines has far-reaching consequences," the Infectious Disease Society of America (IDSA) said in part of a statement. Some medical and public health organizations had expressed concerns at the officials' change to vaccine recommendations without the input of independent advisers. "Federal vaccine recommendations have traditionally been developed by medical and public health experts who gather openly to review evidence and receive public input before recommending what vaccines are needed and who should be eligible for them. Conclusions are based on the best available science, and recommendations are communicated with precision and clarity, providing guidance to clinicians to make the best decisions with their patients," part of the IDSA statement read.